Please use this identifier to cite or link to this item:
|Title:||Oxidative bioactivation and toxicity of leflunomide in immortalized human hepatocytes and kinetics of the non-enzymatic conversion to its major metabolite, A77 1726||Authors:||Seah, Q.M.
|Issue Date:||Aug-2008||Citation:||Seah, Q.M.,New, L.-S.,Chan, E.C.Y.,Boelsterli, U.A. (2008-08). Oxidative bioactivation and toxicity of leflunomide in immortalized human hepatocytes and kinetics of the non-enzymatic conversion to its major metabolite, A77 1726. Drug Metabolism Letters 2 (3) : 153-157. ScholarBank@NUS Repository. https://doi.org/10.2174/187231208785425791||Abstract:||We used immortalized human hepatocytes to study the bioactivation of leflunomide and the metabolic degradation to its major metabolite, A77 1726. Both leflunomide and A77 1726 caused a time- and concentration-dependent increase in LDH release. The cytotoxicity of leflunomide, but not that of A77 1726, was prevented by the pan-CYP inhibitor, 1-aminobenzotriazole, indicating that an oxidative metabolite(s) was responsible for the cell Injury. LC/MS/MS analysis revealed that leflunomide was rapidly degraded in hepatocytes biphasically (t12a = 1.5 h, t1/2 b >24 h), but much slower in cell-free medium (t1/2 >24 h). In contrast, the generation of A77 1726 occurred at a similar rate in cells and cell-free systems. In conclusion, leflunomide was rapidly metabolized in human hepatocytes to A77 1726, but its toxicity was dependent on other, CYP-dependent intermediates. © 2008 Bentham Science Publishers Ltd.||Source Title:||Drug Metabolism Letters||URI:||http://scholarbank.nus.edu.sg/handle/10635/106191||ISSN:||18723128||DOI:||10.2174/187231208785425791|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Nov 20, 2019
checked on Nov 9, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.